10x Genomics (TXG) Stock Price, News & Analysis

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TXG shares.
View TXG analyst ratings or view top-rated stocks.

9 equities research analysts have issued 1 year price targets for 10x Genomics' stock. Their TXG share price targets range from $45.00 to $75.00. On average, they expect the company's stock price to reach $60.22 in the next twelve months. This suggests a possible upside of 113.8% from the stock's current price.
View analysts price targets for TXG or view top-rated stocks among Wall Street analysts.

10x Genomics' stock was trading at $55.96 at the beginning of 2024. Since then, TXG shares have decreased by 49.7% and is now trading at $28.17.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our TXG earnings forecast.

10x Genomics will be holding an earnings conference call on Tuesday, April 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

10x Genomics, Inc. (NASDAQ:TXG) issued its earnings results on Thursday, February, 15th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.05. The business earned $183.98 million during the quarter, compared to analysts' expectations of $182.73 million. 10x Genomics had a negative net margin of 41.17% and a negative trailing twelve-month return on equity of 28.82%. 10x Genomics's revenue was up 17.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.15) earnings per share.

ETFs with the largest weight of 10x Genomics (NASDAQ:TXG) stock in their portfolio include Sprott Junior Gold Miners ETF (SGDJ), ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), Sprott Gold Miners ETF (SGDM), U.S. Global GO GOLD and Precious Metal Miners ETF (GOAU), ARK Innovation ETF (ARKK), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Fidelity Disruptive Medicine ETF (FMED).

10x Genomics issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $670.0 million-$690.0 million, compared to the consensus revenue estimate of $702.1 million.

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

10x Genomics (TXG) raised $297 million in an initial public offering on Thursday, September 12th 2019. The company issued 9,000,000 shares at $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

10x Genomics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (3.04%), Mirador Capital Partners LP (0.02%), Banque Cantonale Vaudoise (0.01%), Handelsinvest Investeringsforvaltning (0.00%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, James Wilbur, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends.

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.